Cargando…

A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy

A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciorati, Clara, Miglietta, Daniela, Buono, Roberta, Pisa, Viviana, Cattaneo, Dario, Azzoni, Emanuele, Brunelli, Silvia, Clementi, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134707/
https://www.ncbi.nlm.nih.gov/pubmed/21609764
http://dx.doi.org/10.1016/j.phrs.2011.05.003
_version_ 1782208005512626176
author Sciorati, Clara
Miglietta, Daniela
Buono, Roberta
Pisa, Viviana
Cattaneo, Dario
Azzoni, Emanuele
Brunelli, Silvia
Clementi, Emilio
author_facet Sciorati, Clara
Miglietta, Daniela
Buono, Roberta
Pisa, Viviana
Cattaneo, Dario
Azzoni, Emanuele
Brunelli, Silvia
Clementi, Emilio
author_sort Sciorati, Clara
collection PubMed
description A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have analysed the effects of a derivative of ibuprofen, NCX 320, belonging to the class of cyclooxygenase inhibiting nitric oxide donator (CINOD), in the α-sarcoglycan null mice, a severe mouse model of dystrophy. NCX 320 was administered daily in the diet for 8 months starting 1 month from weaning. Muscle functional recovery was evaluated by free wheel and treadmill tests at 8 months. Serum creatine kinase activity, as well as the number of diaphragm inflammatory infiltrates and necrotic fibres, was measured as indexes of skeletal muscle damage. Muscle regeneration was evaluated in diaphragm and tibialis anterior muscles, measuring the numbers of centronucleated fibres and of myogenic precursor cells. NCX 320 mitigated muscle damage, reducing significantly serum creatine kinase activity, the number of necrotic fibres and inflammatory infiltrates. Moreover, NCX 320 stimulated muscle regeneration increasing significantly the number of myogenic precursor cells and regenerating fibres. All these effects concurred in inducing a significant improvement of muscle function, as assessed by both free wheel and treadmill tests. These results describe the properties of a new compound incorporating nitric oxide donation together with anti-inflammatory properties, showing that it is effective in slowing muscle dystrophy progression long term. Of importance, this new compound deserves specific attention for its potential in the therapy of muscular dystrophy given that ibuprofen is well tolerated in paediatric patients and with a profile of safety that makes it suitable for chronic treatment such as the one required in muscular dystrophies.
format Online
Article
Text
id pubmed-3134707
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-31347072011-09-01 A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy Sciorati, Clara Miglietta, Daniela Buono, Roberta Pisa, Viviana Cattaneo, Dario Azzoni, Emanuele Brunelli, Silvia Clementi, Emilio Pharmacol Res Article A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have analysed the effects of a derivative of ibuprofen, NCX 320, belonging to the class of cyclooxygenase inhibiting nitric oxide donator (CINOD), in the α-sarcoglycan null mice, a severe mouse model of dystrophy. NCX 320 was administered daily in the diet for 8 months starting 1 month from weaning. Muscle functional recovery was evaluated by free wheel and treadmill tests at 8 months. Serum creatine kinase activity, as well as the number of diaphragm inflammatory infiltrates and necrotic fibres, was measured as indexes of skeletal muscle damage. Muscle regeneration was evaluated in diaphragm and tibialis anterior muscles, measuring the numbers of centronucleated fibres and of myogenic precursor cells. NCX 320 mitigated muscle damage, reducing significantly serum creatine kinase activity, the number of necrotic fibres and inflammatory infiltrates. Moreover, NCX 320 stimulated muscle regeneration increasing significantly the number of myogenic precursor cells and regenerating fibres. All these effects concurred in inducing a significant improvement of muscle function, as assessed by both free wheel and treadmill tests. These results describe the properties of a new compound incorporating nitric oxide donation together with anti-inflammatory properties, showing that it is effective in slowing muscle dystrophy progression long term. Of importance, this new compound deserves specific attention for its potential in the therapy of muscular dystrophy given that ibuprofen is well tolerated in paediatric patients and with a profile of safety that makes it suitable for chronic treatment such as the one required in muscular dystrophies. Academic Press 2011-09 /pmc/articles/PMC3134707/ /pubmed/21609764 http://dx.doi.org/10.1016/j.phrs.2011.05.003 Text en © 2011 Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/ Open Access under CC BY-NC-ND 3.0 (https://creativecommons.org/licenses/by-nc-nd/3.0/) license
spellingShingle Article
Sciorati, Clara
Miglietta, Daniela
Buono, Roberta
Pisa, Viviana
Cattaneo, Dario
Azzoni, Emanuele
Brunelli, Silvia
Clementi, Emilio
A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
title A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
title_full A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
title_fullStr A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
title_full_unstemmed A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
title_short A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
title_sort dual acting compound releasing nitric oxide (no) and ibuprofen, ncx 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134707/
https://www.ncbi.nlm.nih.gov/pubmed/21609764
http://dx.doi.org/10.1016/j.phrs.2011.05.003
work_keys_str_mv AT scioraticlara adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT migliettadaniela adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT buonoroberta adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT pisaviviana adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT cattaneodario adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT azzoniemanuele adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT brunellisilvia adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT clementiemilio adualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT scioraticlara dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT migliettadaniela dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT buonoroberta dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT pisaviviana dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT cattaneodario dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT azzoniemanuele dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT brunellisilvia dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy
AT clementiemilio dualactingcompoundreleasingnitricoxidenoandibuprofenncx320showssignificanttherapeuticeffectsinamousemodelofmusculardystrophy